Zymeworks Inc ZYME.OQ ZYME.O is expected to show a rise in quarterly revenue when it reports results on August 7 for the period ending June 30 2025
The Middletown Delaware-based company is expected to report a 0.7% increase in revenue to $19.375 million from $19.24 million a year ago, according to the mean estimate from 6 analysts, based on LSEG data.
LSEG's mean analyst estimate for Zymeworks Inc is for a loss of 49 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Zymeworks Inc is $19.50, about 35.7% above its last closing price of $12.54
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | -0.40 | -0.41 | -0.30 | Beat | 26.6 |
Dec. 31 2025 | -0.17 | -0.10 | -0.31 | Missed | -213.1 |
Sep. 30 2024 | -0.31 | -0.40 | -0.39 | Beat | 1.4 |
Jun. 30 2024 | -0.33 | -0.32 | -0.27 | Beat | 14.7 |
Mar. 31 2024 | -0.29 | -0.29 | -0.42 | Missed | -44.8 |
Dec. 31 2023 | -0.46 | -0.43 | -0.20 | Beat | 53.9 |
Sep. 30 2023 | -0.50 | -0.47 | -0.41 | Beat | 12.7 |
Jun. 30 2023 | -0.49 | -0.47 | -0.76 | Missed | -61.6 |
This summary was machine generated August 5 at 22:58 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)